Cardiac markers in the diagnosis of acute coronary syndromes

Willems JL, Abreu-Lima C, ArnaudP,et al.: The diagnostic performance of computer programs for the interpretation of electrocardiograms. N Engl J Med 1991, 325:1767–1773. Yusuf S, Pearson M, Sterry H, et al.: The entry ECG in the early diagnosis and prognostic stratification of patients with suspected acute myocardial infarction. Eur Heart J 1984, 5:690–696. McQueen MJ, Holder D, El Maraghi NR: Assessment of the accuracy of serial electrocardiograms in the diagnosis of myocardial infarction. Am Heart J 1983, 105:258–261. Collinson PO, Premachandram S, Hashemi K: Prospective audit of incidence of prognostically important myocardial damage in patients discharged from emergency department. BMJ 2000, 320:1702–1705. Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group: Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. [published erratum appears in Lancet 1994, 343:742]. Lancet 1994, 343:311–322. Bucher HC, Hengstler P, Schindler C, Guyatt GH: Percutaneous transluminal coronary angioplasty versus medical treatment for non-acute coronary heart disease: meta-analysis of randomised controlled trials. Br Med J 2000, 321:73–77. Roxin LE, Cullhed I, Groth T, et al.: The value of serum myoglobin determinations in the early diagnosis of acute myocardial infarction. Acta Med Scand 1984, 215:417–425. Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature. Circulation 1979, 59:607–609. Adams JN, Jamieson M, Trent RJ, et al.: The risks of thrombolysis in patients without acute myocardial infarction. Int J Cardiol 1995, 51:177–181. Lee TH, Goldman L: Serum enzyme assays in the diagnosis of acute myocardial infarction: recommendations based on a quantitative analysis. Ann Intern Med 1986, 105:221–233. Leung FY, Galbraith LV, Jablonsky G, Henderson AR: Re-evaluation of the diagnostic utility of serum total creatine kinase and creatine kinase-2 in myocardial infarction [published errata appear in Clin Chem 1989, 35:2257 and Clin Chem 1990, 36:1530]. Clin Chem 1989, 35:1435–1440. Mair J, Artner-Dworzak E, Dienstl A, et al.: Early detection of acute myocardial infarction by measurement of mass concentration of creatine kinase-MB. Am J Cardiol 1991, 68:1545–1550. Collinson PO, Rosalki SB, Kuwana T, et al.: Early diagnosis of acute myocardial infarction by CK-MB mass measurements. Ann Clin Biochem 1992, 29(Pt 1):43–47. Collinson PO, Rosalki SB, Flather M, et al.: Early diagnosis of myocardial infarction by timed sequential enzyme measurements. Ann Clin Biochem 1988, 25(Pt 4):376–382. Mair J, Smidt J, Lechleitner P, et al.: Rapid accurate diagnosis of acute myocardial infarction in patients with non-traumatic chest pain within 1 h of admission. Coron Artery Dis 1995, 6:539–545. Collinson PO, Ramhamadamy EM, Stubbs PJ, et al.: Rapid enzyme diagnosis of patients with acute chest pain reduces patient stay in the coronary care unit. Ann Clin Biochem 1993, 30(Pt 1):17–22. Gibler WB, Runyon JP, Levy RC, et al.: A rapid diagnostic and treatment center for patients with chest pain in the emergency department. Ann Emerg Med 1995, 25:1–8. Wu AH, Valdes Jr. R, Apple FS, et al.: Cardiac troponin- T immunoassay for diagnosis of acute myocardial infarction. Clin Chem 1994, 40:900–907. Gerhardt W, Katus H, Ravkilde J, et al.: S-troponin T in suspected ischemic myocardial injury compared with mass and catalytic concentrations of S-creatine kinase isoenzyme MB. Clin Chem 1991, 37:1405–1411. Collinson PO, Chandler HA, Stubbs PJ, et al.: Measurement of serum troponin T, creatine kinase MB isoenzyme, and total creatine kinase following arduous physical training. Ann Clin Biochem 1995, 32(Pt 5):450–453. Hamm CW, Ravkilde J, Gerhardt W, et al.: The prognostic value of serum troponin T in unstable angina. N Engl J Med 1992, 327:146–150. Stubbs P, Collinson P, Moseley D, et al.: Prospective study of the role of cardiac troponin T in patients admitted with unstable angina. BMJ 1996, 313:262–264. Heller GV, Blaustein AS, Wei JY: Implications of increased myocardial isoenzyme level in the presence of normal serum creatine kinase activity. Am J Cardiol 1983, 51:24–27. Clyne CA, Medeiros LJ, Marton KI: The prognostic significance of immunoradiometric CK-MB assay (IRMA) diagnosis of myocardial infarction in patients with low total CK and elevated MB isoenzymes. Am Heart J 1989, 118:901–906. Collinson PO: Troponin T or troponin I or CK-MB (or none)? Eur Heart J 1998, 19 Suppl N:N16-N24. Provides a comprehensive review of the role of CK-MB, cTnT, and cTnI for diagnosis and prognostic risk stratification. Olatidoye AG, Wu AH, Feng YJ, Waters D: Prognostic role of troponin T versus troponin I in unstable angina pectoris for cardiac events with meta-analysis comparing published studies. Am J Cardiol 1998, 81:1405–1410. Systematic review and meta-analysis of the published studies on the use of cTnT and cTnI for prognostic risk stratification. Lindahl B, Venge P, Wallentin L: Relation between troponin T and the risk of subsequent cardiac events in unstable coronary artery disease. The FRISC study group. Circulation 1996, 93:1651–1657. Antman EM, Tanasijevic MJ, Thompson B, et al.: Cardiacspecific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996, 335:1342–1349. Wu AH, Apple FS, Gibler WB, et al.: National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendations for the use of cardiac markers in coronary artery diseases. Clin Chem 1999, 45:1104–1121. Comprehensively gathers the experience of leading workers in the field and reviews the literature on the use of cardiac markers in patients with ischemic heart disease. Panteghini M, Apple FS, Christenson RH, et al.: Use of biochemical markers in acute coronary syndromes: IFCC Scientific Division, Committee on Standardization of Markers of Cardiac Damage. International Federation of Clinical Chemistry. Clin Chem Lab Med 1999, 37:687–693. Myocardial infarction redefined — A consensus document of the joint european society of Cardiology/American college of cardiology committee for the redefinition of myocardial infarction [in process citation]. Eur Heart J 2000, 21:1502–1513. The key document covering all aspects of the evidence for redefinition of AMI. Falk E: Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death: autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation 1985, 71:699–708. Davies MJ, Thomas AC, Knapman PA, Hangartner JR: Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death. Circulation 1986, 73:418–427. Ooi DS, Isotalo PA, Veinot JP: Correlation of antemortem serum creatine kinase, creatine kinase-MB, troponin I, and troponin T with cardiac pathology. Clin Chem 2000, 46:338–344. Topol EJ, Bates ER, Walton JA, Jr., et al.: Community hospital administration of intravenous tissue plasminogen activator in acute myocardial infarction: improved timing, thrombolytic efficacy and ventricular function. J Am Coll Cardiol 1987, 10:1173–1177. Rao AC, Collinson PO, Canepa-Anson R, Joseph SP: Troponin T measurement after myocardial infarction can identify left ventricular ejection of less than 40%. Heart 1998, 80:223–225. Stubbs P, Collinson P, Moseley D, et al.: Prognostic significance of admission troponin T concentrations in patients with myocardial infarction. Circulation 1996, 94:1291–1297. Ramanathan K, Stewart JT, Theroux P, et al.: Admission Troponin T level may predict 90 minute TIMI III flow after thrombolysis. Circulation 1997, 96(Supp l):I270. Lindahl B, Andren B, Ohlsson J, et al.: Noninvasive risk stratification in unstable coronary artery disease: exercise test and biochemical markers. FRISC Study Group. Am J Cardiol 1997, 80:40E-44E. Hamm CW, Goldmann BU, Heeschen C, et al.: Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I. N Engl J Med 1997, 337:1648–1653. Lindahl B, Venge P, Wallentin L: Troponin T dentifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection: Fragmin in Unstable Coronary Artery Disease (FRISC) Study Group. J Am Coll Cardiol 1997, 29:43–48. Demonstrates that low molecular weight heparin therapy is only useful in patients with significant detectable levels of cardiac troponin. Hamm CW, Heeschen C, Goldmann B, et al.: Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels: c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators [published erratum appears in N Engl J Med 1999, 341:548]. N Engl J Med 1999, 340:1623–1629. This paper shows that the benefit of IIb/IIIa antagonists is confined to patients with significant detectable levels of cardiac troponin. Heeschen C, Hamm CW, Goldmann B, et al.: Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators: Platelet Receptor Inhibition in Ischemic Syndrome Management. Lancet 1999, 354:1757–1762. This paper also shows that the benefit of GP IIb/IIIa antagonists is confined to patients with significant detectable levels of cardiac troponin. Fragmin and Fast Revascularisation during In Stability in Coronary Artery Disease Investigators: Invasive compared with non-invasive treatment in unstable coronary- artery disease: FRISC II prospective randomised multicentre study. Lancet 1999, 354:708–715. Lindahl B, Diderholm E, Lagerqvist B, et al.: Invasive vs noninvasive strategy in relation to troponin T level and ECG findings — a FRISC-2 substudy. Eur Heart J 2000, 21:469. Bhayana V, Gougoulias T, Cohoe S, Henderson AR: Discordance between results for serum troponin T and troponin I in renal disease. Clin Chem 1995, 41:312–317. Collinson PO, Stubbs PJ, Rosalki SB: Cardiac troponin T in renal disease [letter; comment]. Clin Chem 1995, 41:1671–1673. Collinson PO, Hadcocks L, Foo Y, et al.: Cardiac troponins in patients with renal dysfunction. Ann Clin Biochem 1998, 35(Pt 3):380–386. Ricchiuti V, Voss EM, Ney A, et al.: Cardiac troponin T isoforms expressed in renal diseased skeletal muscle will not cause false-positive results by the second generation cardiac troponin T assay by Boehringer Mannheim. Clin Chem 1998, 44:1919–1924. Collinson PO, Boa FG, Gaze DC: The measurement of cardiac troponins. Ann Clin Biochem 2001, in press. A comprehensive review of the analytic aspects of cardiac troponin measurement including controversies and interferences.